MG1-neoantigen

N/A

Report date: 2025/03/20 15:00:09

Base Information

Drug NameMG1-neoantigen

Drug Alias Nameneoantigen-based MG1 immunotherapies (Turnstone Biologics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTurnstone Biologics Corp

China Registration ClassN/A

Develop Information

Active CompaniesTurnstone Biologics Corp

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A